The short version of prescription control fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
=== Protein effectiveness === Some have argued that there is little evidence to indicate any benefit to using bodybuilding protein or amino acid supplements. A 2005 overview concluded that "[i]n view of the lack of compelling evidence to the contrary, no additional dietary protein is suggested for healthy adults undertaking resistance or endurance exercise". In contrast, a 2018 systematic review, meta-analysis and meta-regression concluded that, “Dietary protein supplementation significantly enhanced changes in muscle strength and size during prolonged RET in healthy adults.“ (RET is an abbreviation for resistance exercise training.)
Beginning in the 2000s, many countries introduced e-visas and electronic travel authorisations (ETAs) as an alternative to traditional visas. An ETA is a form of pre-arrival registration, which may or may not be officially classified as a visa depending on the issuing jurisdiction, and is required for foreign travellers who are exempt from obtaining a full visa. In contrast to the procedures that typically apply regarding proper visas, under which the traveller normally has no recourse if rejected, if an ETA is rejected, the traveller can choose to apply for a visa instead. In contrast, an e-visa is a visa that travellers can apply for and obtain online, without visiting the issuing state's consular mission or visa agency. The following jurisdictions require certain categories of international travellers to hold an ETA or e-visa to clear border controls upon arrival:
peptide map A characteristic fractionation pattern produced by a particular polypeptide or protein when it is subjected to partial hydrolysis in vitro and the resulting peptide chains are separated by chromatography and/or electrophoresis.
== Research == Flupirtine has been noted for its neuroprotective properties, and has been investigated for possible use in Creutzfeldt–Jakob disease, Alzheimer's disease, and multiple sclerosis. It has also been proposed as a possible treatment for Batten disease. Flupirtine underwent a clinical trial as a treatment for multiple sclerosis and fibromyalgia. Flupirtine showed promise for fibromyalgia due to its different action than the three approved by U.S. FDA drugs: pregabalin, milnacipran, and duloxetine. Additionally, there are case reports regarding flupirtine as a treatment for fibromyalgia. Adeona Pharmaceuticals (now called Synthetic Biologics) sub-licensed its patents for using flupirtine for fibromyalgia to Meda AB in May 2010.
Sources: en.wikipedia.org
Microbiology includes culturing of the bacteria in clinical specimens, such as feces, urine, blood, sputum, cerebrospinal fluid, and synovial fluid, as well as possible infected tissue. The work here is mainly concerned with cultures, to look for suspected pathogens which, if found, are further identified based on biochemical tests. Also, sensitivity testing is carried out to determine whether the pathogen is sensitive or resistant to a suggested medicine. Results are reported with the identified organism(s) and the type and amount of drug(s) that should be prescribed for the patient. Parasitology is where specimens are examined for parasites. For example, fecal samples may be examined for evidence of intestinal parasites such as tapeworms or hookworms. Virology is concerned with identification of viruses in specimens such as blood, urine, and cerebrospinal fluid. Hematology analyzes whole blood specimens to perform full blood counts and includes the examination of blood films. Other specialized tests include cell counts on various bodily fluids. Coagulation testing determines various blood clotting times, coagulation factors, and platelet function. Clinical biochemistry commonly performs dozens of different tests on serum or plasma. These tests, mostly automated, includes quantitative testing for a wide array of substances, such as lipids, blood sugar, enzymes, and hormones. Toxicology is mainly focused on testing for pharmaceutical and recreational drugs. Urine and blood samples are the common specimens.
== Effectiveness == Silicone gel sheeting has remained the first-line therapy stated by international clinical recommendations on scar management. Scar measurements studied in most clinical trials include color (vascularisation and pigmentation), thickness (height: clinical and histological), relief (surface irregularities), pliability (tissue elasticity), and surface area (scar contraction or expansion). Scar elevation index is commonly used to indicate scar improvement. It measures the height of scar tissue compared to the normal surrounding skin. Studies show the effectiveness of silicone gel sheeting in minimizing scar elevation index. Another physical measure is the pliability of the scar tissue, which is also improved by silicone gel sheeting. Scar improvement is generally measured by size reduction, appearance, and calming effect. Silicone gel sheeting addresses the 3 requirements well among scar treatments. Several randomized controlled trials were carried out to assess the effectiveness. Silicone gel sheeting produces a statistically significant reduction in scar thickness and color amelioration. Therefore, it is an evidence-based non-invasive preventive treatment. Results of comparative studies on the effectiveness of silicone gel sheeting and silicone gel do not show significant differences between the two. Another non-invasive treatment is compression therapy, in which patients wear pressure garments to control the growth of scars. Pressure garments apply mechanical pressure to the surface of the scar, reducing the supply of blood and oxygen to the scar tissue.
The sclera forms the posterior five-sixths of the connective tissue coat of the human eyeball. It is continuous with the dura mater and the cornea, and maintains the shape of the eyeball, offering resistance to internal and external forces, and provides an attachment for the extraocular muscle insertions. The sclera is perforated by many nerves and vessels passing through the posterior scleral foramen, the hole that is formed by the optic nerve. At the optic disc, the outer two-thirds of the sclera continues with the dura mater (outer coat of the brain) via the dural sheath of the optic nerve. The inner third joins with some choroidal tissue to form a plate (lamina cribrosa) across the optic nerve with perforations through which the optic fibers (fasciculi) pass. The thickness of the sclera varies from 1 mm at the posterior pole to 0.3 mm just behind the insertions of the four rectus muscles. The sclera's blood vessels are mainly on the surface. Along with the vessels of the conjunctiva (which is a thin layer covering the sclera), those in the episclera render the inflamed eye bright red. In many vertebrates, the sclera is reinforced with plates of cartilage or bone, together forming a circular structure called the scleral ring. In primitive fish, this ring consists of four plates, but the number is lower in many living ray-finned fishes, and much higher in lobe-finned fishes, crocodilians, various reptiles, and birds. The ring has disappeared in many groups, including living amphibians, some reptiles and fish, and all mammals.
Sources: en.wikipedia.org
=== Chemical === The chemistry of nihonium is expected to be very different from that of thallium. This difference stems from the spin–orbit splitting of the 7p shell, which results in nihonium being between two relatively inert closed-shell elements (copernicium and flerovium). Nihonium is expected to be less reactive than thallium, because of the greater stabilisation and resultant chemical inactivity of the 7s subshell in nihonium compared to the 6s subshell in thallium. The standard electrode potential for the Nh+/Nh couple is predicted to be 0.6 V. Nihonium should be a rather noble metal. The metallic group 13 elements are typically found in two oxidation states: +1 and +3. The former results from the involvement of only the single p electron in bonding, and the latter results in the involvement of all three valence electrons, two in the s-subshell and one in the p-subshell. Going down the group, bond energies decrease and the +3 state becomes less stable, as the energy released in forming two additional bonds and attaining the +3 state is not always enough to outweigh the energy needed to involve the s-electrons. Hence, for aluminium and gallium +3 is the most stable state, but +1 gains importance for indium and by thallium it becomes more stable than the +3 state. Nihonium is expected to continue this trend and have +1 as its most stable oxidation state. The simplest possible nihonium compound is the monohydride, NhH. The bonding is provided by the 7p1/2 electron of nihonium and the 1s electron of hydrogen.
The balance-of-power system is discredited today. References to it, even by professional historians and international lawyers, commonly imply either that it was a system for war which repeatedly failed or that it was a system for making war which often succeeded in its purpose … During the period of its dominance as a European system, say, 1648 to 1918, its record in preventing war was certainly not striking. Indeed, it probably was itself responsible for starting more wars than it prevented. Former German Foreign Minister Joschka Fischer interpreted the core of the concept of Europe after 1945 as the rejection of the European balance-of-power principle and the hegemonic ambitions of individual states that had emerged following the Peace of Westphalia in 1648: "European integration was the response to centuries of a precarious balance of powers on this continent which again and again resulted in terrible hegemonic wars and culminated in the two World Wars between 1914 and 1945." Former US Secretary of Defense Dick Cheney expressed the same for Europe and other democracies: "It is not in our interest or those of the other democracies to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional, or even global peace hung in the balance." NATO Secretary General, Manfred Wörner, outlined the European alternative at the end of the Cold War:
In college basketball, the NCAA Division I men's and women's tournaments will expand to 76 teams beginning next year. The Pentagon releases declassified documents about UFOs and extraterrestrial life. May 10 – Six people are found dead inside a boxcar on a Union Pacific freight train in Laredo, Texas. May 12 2025–2026 United States redistricting: The Republican-led South Carolina Senate rejects redistricting efforts to redraw the congressional districts in South Carolina, including efforts to eliminate the seat represented by congressman Jim Clyburn. American autonomous driving technology company Waymo recalls 3,800 robotaxis over risks that they could enter flooded areas.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.